Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RB1 | P06400 | 7/20 | 0.60 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463397 | 0.97 | RB1 (0.61) | RB1CDC42CYP2D6CXCR4MEN1 | |
| SCHEMBL5447201 | 0.94 | RB1 (0.60) | RB1CDC42CYP2D6CXCR4MEN1 | |
| SCHEMBL5445881 | 0.85 | RB1 (0.53) | RB1MEN1GLAMAPTALOX15 | |
| SCHEMBL5454792 | 0.83 | RB1 (0.60) | RB1CDC42CYP2D6MEN1GLA | |
| SCHEMBL5456906 | 0.82 | RB1 (0.54) | RB1CDC42CYP2D6MEN1GLA | |
| SCHEMBL5453907 | 0.82 | RB1 (0.58) | RB1CDC42MEN1GLAMAPT | |
| SCHEMBL5466585 | 0.81 | RB1 (0.56) | RB1CDC42CYP2D6MEN1GLA | |
| SCHEMBL5458538 | 0.81 | RB1 (0.63) | RB1CDC42CYP2D6MEN1GLA | |
| SCHEMBL5468093 | 0.81 | RB1 (0.57) | RB1MEN1GLAMAPTALOX15 | |
| SCHEMBL5466578 | 0.80 | RB1 (0.62) | RB1CDC42CYP2D6MEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | RB1 1821/4885CDC42 1241/4885CYP2D6 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.